Lilly’s antibody for COVID-19 protection starts nursing home trial
LY-CoV555 is a potent, neutralizing IgG 1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19.
Lilly intends to test this first antibody as well as other neutralizing antibodies against SARS-CoV-2 over the next several months.
Lilly intends to test both single antibody therapy as well as combinations of Lilly antibodies (sometimes known as antibody cocktails) as potential therapeutics for COVID-19. CAN READ MORE IN THIS
https://pharmaphorum.com/tag/ly-cov555/
https://www.prnewswire.com/news-releases/lilly-initiates-phase-3-trial-of-ly-cov555-for-prevention-of-covid-19-at-long-term-care-facilities-in-partnership-with-the-national-institute-of-allergy-and-infectious-diseases-niaid-301104445.html